Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etoposide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.94 |
| ▸ | TOP2B known ✓ | Q02880 | 4/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.94 |
| ▸ | GAA | P10253 | 5/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | MEN1 | O00255 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.94 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.94 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.94 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.94 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoposide SCHEMBL14484918 | 1.00 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL16246162 | 1.00 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL2305491 | 1.00 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL14401267 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL22594950 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL24482748 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL13114424 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL20598257 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL23064754 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL6361654 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 39089 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075497-A | Use of NLRP3 agonist for tumor treatment | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| CN-122070142-A | Combination therapy of anti-CD 20/anti-CD 3 bispecific antibodies and chemotherapy in CTDNA high-risk patients | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026102168-A1 | FIRST-LINE COMBINATION THERAPY WITH PLINABULIN FOR TREATING SMALL CELL LUNG CANCER | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | claimed |
| US-20260125428-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | UNIV CONNECTICUT (US) | 2026-05-07 | — | — | US | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-5637680-A | Process for the preparation of etoposide phosphate and intermediate thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1997-06-10 | — | — | US | claimed |
| EP-0771209-A2 | NOVEL PEPTIDES | Merck & Co., Inc. (a New Jersey corp.) (US) | 1997-05-07 | — | — | EP | claimed |
| WO-1997014416-A1 | CONJUGATES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | claimed |
| WO-1997012624-A1 | NOVEL PEPTIDES | MERCK & CO., INC. (US) | 1997-04-10 | — | — | WO | claimed |
| WO-1996039183-A9 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF EFFECTOR MOLECULES | — | 1997-01-30 | — | — | WO | claimed |
| WO-1996039183-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF EFFECTOR MOLECULES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1996000503-A1 | NOVEL PEPTIDES | MERCK & CO., INC. (US) | 1996-01-11 | — | — | WO | claimed |
| EP-0567089-B1 | Process for the preparation of etoposide phosphate and intermediates thereof | NIPPON KAYAKU KK (JP) | 1995-10-25 | — | — | EP | claimed |
| EP-0567089-A1 | Process for the preparation of etoposide phosphate and intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1993-10-27 | — | — | EP | claimed |
| WO-1989011299-A1 | METHOD FOR DELIVERY OF THERAPEUTIC AGENTS TO TARGET BRAIN TISSUE USING MONOCLONAL ANTIBODY CONJUGATES | STATE OF OREGON ACTING BY AND THROUGH THE STATE BO (US) | 1989-11-30 | — | — | WO | claimed |